Mrs. Casey is a 47-year-old woman. She was diagnosed with T2D about 4 years ago and has stage 3b CKD. Her T2D is currently managed with metformin plus SGLT2 inhibitor combination therapy. Today, her A1C is above her individualized goal at 8.2%. Based on findings from the FLOW trial, which of the following may be added to improve her glucose control and help slow progression of her CKD? A. Pioglitazone B. Injectable semaglutide C. Tirzepatide D. Linagliptin
[Expert Solution]: Mrs
Need help with your Clinical Case Studies case study or NCLEX preparation? Connect with a verified Nursing expert now.